Document is current
Any future updates will be listed below
-
Authors
Netskar, Herman https://orcid.org/0000-0002-3081-9581
Pfefferle, Aline https://orcid.org/0000-0002-8181-537X
Goodridge, Jodie P.
Sohlberg, Ebba https://orcid.org/0000-0003-1942-0040
Dufva, Olli
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Brownlie, Demi https://orcid.org/0000-0001-5932-6425
Michaëlsson, Jakob
Marquardt, Nicole https://orcid.org/0000-0003-3186-4752
Clancy, Trevor https://orcid.org/0000-0001-9896-0613
Horowitz, Amir
Malmberg, Karl-Johan https://orcid.org/0000-0002-8718-9373
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (223310, 2021-03069)
Cancerfonden (21-1793Pj, 23-2946Pj)
Barncancerfonden (PR2020-1059)
Norges Forskningsråd (275469, 237579)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2021-073, 2024-053)
Knut och Alice Wallenbergs Stiftelse
Stiftelsen för Strategisk Forskning
VINNOVA
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 25 October 2023
Accepted: 30 May 2024
First Online: 2 July 2024
Competing interests
: J.P.G. is an employee at Fate Therapeutics. T.C. is an employee at NEC OncoImmunity AS. K.-J.M. is a consultant at Fate Therapeutics and Vycellix and has research support from Fate Therapeutics, Oncopeptides for studies unrelated to this work. O.D. has received research funding from Gilead Sciences and Incyte, unrelated to this work, and personal fees from Sanofi, unrelated to this work. S.A.T. is a scientific advisory board member of ForeSite Labs, QIAGEN and Element Biosciences, and a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics, and a part-time employee of GlaxoSmithKline. A.H. has received funding from Astra Zeneca/MedImmune, unrelated to this work. A.H. is a consultant at Purple BioTech. The other authors declare no competing interests.
